RFL Rafael Holdings Inc Class B

Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.

$5.38  -0.31 (-5.45%)
As of 12/03/2021 10:50:31 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Real Estate
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/27/2018
Outstanding shares:  20,699,953
Average volume:  446,834
Market cap:   $116,333,736
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    75062E106
ISIN:        US75062E1064
Sedol:      BFWZ8G9
Valuation   (See tab for details)
PE ratio:   -4.80
PB ratio:   0.82
PS ratio:   29.30
Return on equity:   -20.07%
Net income %:   -618.08%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy